1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology; Ovarian Cancer NCCN Guidelines Version 3.2014, Small Cell Lung Cancer NCCN Guidelines Version 2.2014, Cervical Cancer NCCN Guidelines Version 1.2015, Non-Hodgkin’s Lymphoma NCCN Guidelines Version 2. 2015, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed Dec 8, 2015
2. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanecarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432–5438
3. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
4. Ando Y, Shimokata T, Yasuda Y, Hasegwa Y (2014) Carboplatin dosing for adult Japanese patients. Nagoya J Med Sci 76:1–9
5. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200